The termination of the dynamic zero COVID-19 strategy and the subsequent resurgence of COVID-19 in China led to a marked increase in ON and provided us a chance to investigate the prevalence of serum AQP4-Ab and MOG-Ab in ON patients after SARS-CoV-2 infection. This evidence concerns the gene MOG and COVID-19.